GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Xeris Biopharma
Xeris Biopharma owns technologies that enable the creation of ready-to-use liquid injectable formulations. Its share price reflects both sales of its own products and partnerships with other pharmaceutical companies that utilize its technologies.
Share prices of companies in the market segment - Specialized pharma
Xeris Biopharma possesses technologies that enable the creation of ready-to-use liquid injectable formulations. This is its core segment. We classify it as a Specialized Pharma company, and the chart below reflects the dynamics of the entire drug development industry.
Broad Market Index - GURU.Markets
Xeris Biopharma is a pharmaceutical company that uses its technologies to create ready-to-use injectable and infusion medications. It is a component of the GURU.Markets index. The chart below represents the market. See how Xeris shares compare to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
XERS - Daily change in the company's share price Xeris Biopharma
Daily fluctuations in Xeris Biopharma, a specialist in ready-to-use injectables, reflect the volatility of the pharmaceutical sector. Change_co measures sensitivity to regulatory approvals. This metric forms the basis for analysis in the niche pharmaceutical sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Xeris Biopharma Holdings, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to XERS, with its unique technology for creating ready-to-use injections, helps assess its risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Xeris Biopharma is a company that has developed technology for creating ready-to-use injectable and infusion medications. Its business model is based on partnerships with major pharmaceutical companies. The chart below illustrates the volatility of the biotech sector, which is interesting to compare with Xeris's unique story.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Xeris Biopharma
Xeris is a biopharmaceutical company specializing in ready-to-use injectables. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Xeris Biopharma Holdings, Inc. is a pharmaceutical company with a unique technology that enables the creation of ready-to-use injectable drugs. This chart shows how its innovative platform, partnerships with major pharmaceutical companies, and the commercialization of its own products influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xeris Biopharma is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Xeris Biopharma
The market capitalization of Xeris, a biopharmaceutical company, depends on the commercial success of its products. The monthly fluctuations on the chart reflect sales data for its ready-to-use injectables and the success of its unique technology in developing new drugs.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company using its proprietary technologies to develop ready-to-use injectable and infusion products. The dynamics of its sector, shown in the chart, serve as background information. It is interesting to assess how its technologies, addressing drug stability and dosing challenges, create value in partnerships and its own products.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xeris Biopharma is a pharmaceutical company with technology that enables the creation of ready-to-use injectable drugs that previously required compounding. This full-market performance chart allows us to assess how Xeris's stock is performing as it transitions from development to commercial growth, and how its unique product allows it to withstand overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Xeris Biopharma
Xeris Biopharma, a pharmaceutical company developing ready-to-use injectables, whose weekly stock price performance depends on the success of its product commercialization and clinical trial data. News about partnerships and regulatory approvals shape short-term trends.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Xeris Biopharma, like other specialty pharmaceutical companies, is part of a volatile sector. This chart compares its performance with the industry to see how much of its weekly fluctuations are driven by general pharma regulatory news and how much by product-specific approvals.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Xeris Biopharma is a pharmaceutical company with technology that enables the creation of ready-to-use injectable drugs. This chart will help you assess whether Xeris shares are moving independently of the market, driven by approval news, or following general trends in the biotech sector.
Market capitalization of the company, segment and market as a whole
XERS - Market capitalization of the company Xeris Biopharma
Xeris Biopharma's market capitalization is a financial story of innovation in drug delivery. The company's stock price reflects its ability to create ready-to-use liquid formulations of drugs previously available only as powders. Its growth reflects its commitment to convenience and ease of use as key advantages in the pharmaceutical market.
XERS - Share of the company's market capitalization Xeris Biopharma within the market segment - Specialized pharma
Xeris Biopharma is a pharmaceutical company that uses its innovative technologies to develop ready-to-use injectable and infusion medications. Its market share reflects the potential of its platform to improve existing drugs. The chart below shows how the market perceives its ability to create more patient-friendly products.
Market capitalization of the market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectable medications. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Xeris is addressing the important issue of convenient and safe drug administration.
Market capitalization of all companies included in a broad market index - GURU.Markets
Xeris Biopharma is a company that has developed technology that enables the creation of ready-to-use liquid forms of medications previously available only in powder form. Its market capitalization chart tells a story of convenience and innovation in drug delivery, demonstrating how improving the user experience is changing the pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
XERS - Book value capitalization of the company Xeris Biopharma
Xeris Biopharma's book value is its production capacity and capital. The chart below shows the material and financial basis for the development and commercialization of its innovative injectable drugs. Its growth reflects investments in its unique technology platform.
XERS - Share of the company's book capitalization Xeris Biopharma within the market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectable medications. Its technology eliminates the need for complex drug mixing. Manufacturing requires specialized facilities. The chart below shows how the company is building its physical infrastructure for the production of innovative products.
Market segment balance sheet capitalization - Specialized pharma
Xeris Biopharma develops ready-to-use injectables. Its technology enables the creation of stable liquid drug formulations, which could reduce dependence on complex cold chain management. The chart below shows how its book value reflects investment in this unique R&D platform, rather than mass production.
Book value of all companies included in the broad market index - GURU.Markets
Xeris Biopharma's book value lies in its technology, which is transforming the way drugs are administered. The company's assets include not only laboratories but also manufacturing facilities for the creation of ready-to-use injectables. This material base enables the transformation of complex drugs that require mixing into simple and convenient injections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Xeris Biopharma
Xeris Biopharma develops ready-to-use injectables. Its book value is small, but its market capitalization reflects the value of its patented XeriSol and XeriJect technologies, which enable the creation of stable liquid drug formulations. This represents a premium for solving an important problem in pharmaceuticals.
Market to book capitalization ratio in a market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectables, simplifying drug administration. Its value lies in its patented technology, not its manufacturing facilities. The chart shows the premium the market pays for this innovative platform and its product potential compared to its modest tangible assets.
Market to book capitalization ratio for the market as a whole
Xeris Biopharma develops ready-to-use injectable and infusion medications. The company's value lies in its patented technology, which enables the creation of stable liquid drug formulations. The graph shows how the market places a premium on a technological platform capable of solving real-world problems in drug use, valuing it above tangible assets.
Debts of the company, segment and market as a whole
XERS - Company debts Xeris Biopharma
Xeris Biopharma, a company developing ready-to-use injectables, uses debt to finance the commercialization of its products and clinical trials. This chart shows how the company invests in marketing for already approved drugs and advances new candidates through the trial stages, narrowing the gap to profitability.
Market segment debts - Specialized pharma
Xeris Biopharma develops ready-to-use injectable and infusion medications. For a specialty pharmaceutical company, debt can be a way to finance the launch of new products and expand manufacturing capabilities. The chart shows how Xeris's financial strategy supports its niche business model compared to larger pharmaceutical companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Xeris Biopharma
Xeris Biopharma develops ready-to-use injectables, simplifying drug administration. Commercializing new pharmaceutical products requires significant investment in production and marketing. This chart shows whether the company is using debt to finance this process, which can be risky until stable sales volumes are achieved.
Market segment debt to market segment book capitalization - Specialized pharma
Xeris Biopharma develops ready-to-use injectable and infusion medications using its proprietary technologies. This solves the problem of complex drug compounding. The chart shows the overall debt burden in the pharmaceutical industry, helping to understand how the company finances the commercialization of its innovative, yet niche, products.
Debt to book value of all companies in the market
Xeris Biopharma, specializing in ready-to-use medications, is solving a critical problem in medicine. This chart shows the overall market leverage. It helps assess how easy or difficult it is for niche pharmaceutical companies to raise capital to commercialize their products, depending on the overall risk appetite of investors.
P/E of the company, segment and market as a whole
P/E - Xeris Biopharma
Xeris Biopharma develops ready-to-use injectables, solving the problem of complex drug mixing. This chart shows how investors assess the commercial potential of this technology. The rising value reflects the belief that the convenience and safety of Xeris' products will enable them to capture significant market share in their therapeutic niches.
P/E of the market segment - Specialized pharma
Xeris Biopharma operates in the specialty pharmaceuticals sector. This chart shows the average P/E for this industry. A company's P/E is higher than the industry average, indicating that investors highly value its ready-to-use injectable technology and believe it can capture significant market share in its therapeutic niches.
P/E of the market as a whole
Xeris Biopharma develops ready-to-use injectable and infusion products, solving the problem of complex drug mixing. Its success depends on the commercialization of this technology. This chart reflects the overall sentiment in the pharmaceutical industry. It allows us to assess whether the market perceives Xeris as a company with a breakthrough technological platform or as a niche player with limited potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Xeris Biopharma
Xeris Biopharma develops and commercializes ready-to-use injectable and infusion products using its innovative technologies. This graph reflects investor expectations for the commercial success of its products, such as Gvoke for the treatment of hypoglycemia. This valuation is dependent on sales growth and approval of new dosage forms.
%20P%2FE%20Xeris%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Xeris-Biopharma&v=1772513894708 "Chart of the company's future (projected) P/E Xeris Biopharma")
Future (projected) P/E of the market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectable and infusion medications using its XeriSol and XeriJect technologies. This chart compares the company's future profitability expectations with those of the pharmaceutical sector. It demonstrates the extent to which investors believe in the commercial potential of its technologies and its ability to partner with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772513894733 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Xeris Biopharma develops ready-to-use injectable and infusion medications, improving existing treatments. The company's success depends on regulatory approval and physician acceptance of its technologies. The overall market environment, illustrated in this chart, influences the availability of capital for R&D and commercialization, which is critical for pharmaceutical innovators.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513894750 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Xeris Biopharma
Xeris Biopharma develops and commercializes ready-to-use injectable and infusion products. The company's financial success depends on sales volumes of its existing products and the successful launch of new dosage forms. This chart illustrates how commercial efforts and clinical trial results shape the company's path to sustainable profitability.
Profit of companies in the market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectable and infusion products, solving the challenges associated with complex drug reconstitution. This graph, showing overall pharmaceutical sector revenue, reflects the value of innovation in drug delivery. Xeris's technologies, which simplify drug administration, directly impact market potential and profitability in its therapeutic niches.
Overall market profit
Xeris Biopharma has developed innovative technologies for creating ready-to-use injectable medications. This solves the problem of complex drug mixing, improving safety and convenience for patients. The company's success depends on the adoption of its technologies within the pharmaceutical industry, rather than on general economic trends, which is typical for niche innovators.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Xeris Biopharma
Xeris Biopharma develops and commercializes ready-to-use injectable and infusion medications. Future revenue projections in this chart depend on the sales success of existing products and the approval of new ones. Analysts are evaluating the potential of the company's XeriSol technology, which enables the creation of stable liquid drug formulations.
%20profit%20of%20the%20company%20Xeris%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Xeris-Biopharma&v=1772513894837 "Graph of future (projected) profit of the company Xeris Biopharma")
Future (predicted) profit of companies in the market segment - Specialized pharma
Xeris Biopharma develops ready-to-use injectable and infusion products, simplifying drug delivery. This chart shows revenue forecasts for the specialty pharmaceuticals sector. It helps assess how the company's technology, which solves practical problems in medicine, fits into the overall expectations of innovations that improve therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772513894897 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Xeris Biopharma develops ready-to-use injectable medications. The company addresses the complexities of mixing medications before administration. Demand for such convenient products in medicine is stable. However, overall economic conditions, reflected in this chart, impact the adoption rate of new technologies by hospitals, which may face budget constraints during recessions.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513894910 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Xeris Biopharma
Xeris Biopharma specializes in developing ready-to-use injectable and infusion medications, simplifying their administration. This multiple, which links market value to sales, reflects the value of its technology. It shows the premium investors pay for its ability to improve existing drugs, making them more convenient for patients and doctors.
P/S market segment - Specialized pharma
Xeris Biopharma develops and commercializes ready-to-use injectable and infusion medications using its innovative technology platform. This simplifies drug administration for patients and physicians. This chart reflects how investors value pharmaceutical revenue, demonstrating how the market values Xeris' technology and its ability to improve existing treatments.
P/S of the market as a whole
Xeris Biopharma Holdings uses its innovative technologies to develop ready-to-use injectable and infusion products. The company aims to simplify drug delivery and improve patients' lives. This chart helps understand how the market values biotech platforms aimed at improving existing therapies, relative to overall revenue estimates.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Xeris Biopharma
Xeris Biopharma Holdings develops and commercializes ready-to-use injectable and infusion medications. This chart shows how investors value the company based on its projected future sales. It reflects the market's confidence in the company's technology, which simplifies drug delivery, and its success in commercializing new products.
%20P%2FS%20Xeris%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Xeris-Biopharma&v=1772513895041 "The graph of the company's future (projected) P/S Xeris Biopharma")
Future (projected) P/S of the market segment - Specialized pharma
Xeris Biopharma Holdings uses its non-aqueous technologies to develop ready-to-use injectable and infusion products. This chart compares investor expectations for its future revenue with the sector. A forward estimate may signal confidence in the commercial success of its existing products and the potential of its technology platform for developing new drugs.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772513895144 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Xeris Biopharma develops ready-to-use injectables, solving the problem of complex drug mixing. The company's success depends on the implementation of its technologies in clinical practice. This graph of investor expectations reflects their belief in innovations that can improve healthcare and create new revenue streams in the pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513895177 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Xeris Biopharma
This chart illustrates Xeris Biopharma's commercial success in developing ready-to-use medications. The company's revenue is generated from sales of its innovative products, which do not require complex mixing before administration. Sales growth reflects physicians' and patients' recognition of the convenience and reliability of its patented drug delivery technology.
Sales of companies in the market segment - Specialized pharma
Xeris Biopharma is a biopharmaceutical company that uses its innovative technologies to develop ready-to-use injectable and infusion products. This simplifies drug delivery. This chart represents the total revenue of the entire specialty pharmaceutical market, demonstrating the need for the improved delivery methods offered by Xeris.
Overall market sales
Xeris Biopharma Holdings develops ready-to-use injectable and infusion medications. Its success depends on the approval and adoption of its products in clinical practice. Demand is not cyclical, but the overall economic situation, shown in this chart, affects the solvency of the healthcare system and insurers, which decide which medications to cover.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Xeris Biopharma
Xeris Biopharma is a pharmaceutical company specializing in the development and commercialization of ready-to-use injectable and infusion medications. Its success depends on the market acceptance of its products and the expansion of its portfolio. This chart shows analysts' expectations for sales growth of existing drugs and the potential of new developments.
%20sales%20of%20the%20company%20Xeris%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Xeris-Biopharma&v=1772513895334 "Schedule of future (projected) sales of the company Xeris Biopharma")
Future (projected) sales of companies in the market segment - Specialized pharma
Xeris Biopharma develops and commercializes ready-to-use injectable and infusion products. This chart segments projected sales by their key products, such as Gvoke (for the treatment of hypoglycemia) and Keveyis. This allows us to assess which of their unique technologies and products, according to analysts, have the greatest market potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772513895353 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Investment activity in the biotech sector, as reflected in this graph, is critical for Xeris Biopharma. The company develops ready-to-use injectable drugs. Funding for development and commercialization of these products depends on capital inflows into the industry, which increase when the outlook is favorable.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513895401 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Xeris Biopharma
Xeris Biopharma is a pharmaceutical company that uses its technology to create ready-to-use injectable medications. This chart shows the profitability of its innovative platform. Profitability depends on sales volumes of its own commercial products and payments from partners who use its technology to improve their drugs.
Market segment marginality - Specialized pharma
Xeris Biopharma Holdings specializes in developing ready-to-use injectable and infusion drugs using its proprietary technologies. Profitability depends on the commercial success of its products. This chart shows the average profitability in the pharmaceutical industry. It helps assess the relevance of Xeris' technologies for improving existing drugs.
Market marginality as a whole
Xeris Biopharma develops ready-to-use injectable and infusion medications. The company strives to simplify the administration of complex medications. Its success depends on partnerships with pharmaceutical companies and demand from healthcare systems. This trend, reflecting the overall economic situation, influences healthcare budgets and the willingness to pay for innovative drug delivery methods.
Employees in the company, segment and market as a whole
Number of employees in the company Xeris Biopharma
Xeris Biopharma develops ready-to-use injectable and infusion products using its proprietary technologies. This graph reflects the size of its scientific and commercial teams. The growth in the graph indicates the transition from R&D to commercialization, which requires the creation of an infrastructure for marketing and sales of FDA-approved products.
Share of the company's employees Xeris Biopharma within the market segment - Specialized pharma
Xeris Biopharma has developed innovative technologies that enable the creation of ready-to-use liquid formulations of drugs that were previously only available in powder form. This chart shows the company's share of the total number of specialists in the drug development niche. This reflects its technological leadership and potential to improve existing therapies.
Number of employees in the market segment - Specialized pharma
Xeris Biopharma Holdings develops and commercializes ready-to-use injectable and infusion medications. This chart reflects employment in the specialty pharmaceuticals sector. The growing number of scientists and engineers in this field reflects the demand for innovative dosage forms that simplify drug administration and improve patient quality of life.
Number of employees in the market as a whole
Xeris Biopharma develops ready-to-use injectables, simplifying drug delivery. Their growth depends on partnerships with pharmaceutical companies and the approval of their technologies. This overall employment schedule is not directly relevant to them. Hiring at Xeris is determined by the success of their platform and the expansion of the product portfolio they help stabilize.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Xeris Biopharma (XERS)
Xeris Biopharma is a pharmaceutical company with technology that enables the creation of ready-to-use injectable drugs. Its value lies in this platform and the products built on it. This chart shows how the market values its intellectual property, which addresses important medical problems and creates scalable value.
%20of%20the%20company%20Xeris%20Biopharma%20(XERS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Xeris-Biopharma-XERS&v=1772513895633 "Chart of market capitalization per employee (in thousands of dollars) of the company Xeris Biopharma (XERS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Xeris Biopharma uses its proprietary technologies (XeriSol, XeriJect) to create ready-to-use injectable medications that were previously unstable in liquid form. Their value lies in their R&D platform. This chart shows how the market values their pharmaceutical technology.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772513895662 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Xeris Biopharma develops ready-to-use injectable and infusion medications that simplify their administration. It is a technology-based pharmaceutical company. Its high market valuation per employee, as shown in this chart, reflects the value of its innovative platform and intellectual property, which enables improvements to existing medications.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513895671 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Xeris Biopharma (XERS)
Xeris Biopharma has proprietary technologies (XeriSol/XeriJect) that convert dry drug powders into ready-to-inject liquid forms. This graph reflects their hybrid model: they generate revenue from already commercialized products while simultaneously investing in R&D to apply their technology to new drugs.
%20Chart%20Xeris%20Biopharma%20(XERS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Xeris-Biopharma-XERS&v=1772513895677 "Company Profit Per Employee (in thousands of dollars) Chart Xeris Biopharma (XERS)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Xeris Biopharma is a "specialty" pharma. They "use" R&D (XeriSol/XeriJect platforms) to "create" ready-to-use "injectables" (e.g., Gvoke). This chart shows the benchmark for "specialty pharma." In this "B2B R&D" sector, the benchmark is *high*. Profit per employee is generated by "patents" for the "delivery" "technology" (convenience), not the "drug" itself.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772513895712 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Xeris Biopharma uses its innovative technologies (XeriSol, XeriJect) to create ready-to-use injectable and infusion products. They transform complex powders into stable liquids. This is science-intensive pharmaceuticals. This chart helps understand how cost-effective this model, where value is created through the R&D technology platform, is per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513895722 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Xeris Biopharma (XERS)
Xeris Biopharma develops ready-to-use injectables, simplifying drug administration. Revenue per employee here reflects the commercial success of its innovative products. The graph shows how sales of patented formulations generate revenue, demonstrating the company's ability to carve out a niche in the pharmaceutical market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Xeris-Biopharma-XERS&v=1772513895765 "Sales chart per company employee Xeris Biopharma (XERS)")
Sales per employee in the market segment - Specialized pharma
Xeris Biopharma has developed technology platforms (XeriSol, XeriJect) that enable the creation of ready-to-use liquid injectables (e.g., glucagon rescue syringes). This graph shows their success in commercializing their technology—both through their own products and through partnerships with other pharmaceutical companies.
Sales per employee for the market as a whole
Xeris Biopharma (XERS) is a pharmaceutical company that uses its proprietary technologies (XeriSol, XeriJect) to create ready-to-use injectable medications that were previously unstable. This chart demonstrates the effectiveness of their technology platform. By selling its own niche medications (such as Gvoke for diabetes) and licensing its technology, Xeris can generate significant revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Xeris Biopharma (XERS)
Xeris Biopharma uses its proprietary technologies (XeriSol, XeriJect) to create ready-to-use injectable medications that were previously unstable in liquid form. This chart suggests bearish bets. Skeptics may doubt the commercial success of their existing products (like Gvoke for hypoglycemia) or that their technology platform will attract sufficient partners from Big Pharma.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Xeris-Biopharma-XERS&v=1772513895923 "Short Shares Chart for the Company Xeris Biopharma (XERS)")
Shares shorted by market segment - Specialized pharma
Xeris Biopharma (XERS) specializes in developing ready-to-use injectable medications (for example, for hypoglycemia). Their XeriSol technology stabilizes medications in liquid form. This chart shows the betting against the specialty pharma sector. If investors are short the industry, they may doubt the commercial potential of niche drugs or anticipate patent issues.
Shares shorted by the overall market
Xeris (XERS) is a biotech focused on ready-to-use injections. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Xeris Biopharma (XERS)
Xeris Biopharma develops ready-to-use injectables. Success depends on approval and sales. This chart can soar above 70 on positive FDA news or strong sales, but this is a risk zone. Below 30 is often associated with trial failures, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Xeris-Biopharma-XERS&v=1772513896004 "RSI 14 indicator chart for the company's stock Xeris Biopharma (XERS)")
RSI 14 Market Segment - Specialized pharma
Xeris Biopharma uses its proprietary technologies (XeriSol, XeriJect) to create ready-to-use injectables that were previously unstable in liquid form. This chart shows the overall sentiment in the specialty pharmaceutical sector. It helps us understand whether Xeris's momentum is driven by its unique technology platform or is a general "wave" across the industry.
RSI 14 for the overall market
Xeris Biopharma (XERS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XERS (Xeris Biopharma)
Xeris Biopharma specializes in developing ready-to-use injectables, solving drug compounding issues. This chart shows the average analyst forecast. Their targets are based on sales growth for key products (Gvoke, Keveyis) and the successful application of their XeriSol technology to new drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XERS-Xeris-Biopharma&v=1772513896149 "A chart showing analyst consensus forecasts for the expected stock price. XERS (Xeris Biopharma)")
The difference between the consensus estimate and the actual stock price XERS (Xeris Biopharma)
Xeris Biopharma (XERS) is a pharmaceutical company that uses its technology platform (XeriSol, XeriJect) to create ready-to-use injectables. This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XERS-Xeris-Biopharma&v=1772513896242 "A chart showing the difference between the consensus forecast and the actual stock price. XERS (Xeris Biopharma)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Xeris Biopharma is a pharmaceutical company that uses its formulation technologies to create more convenient versions of existing drugs (for example, ready-to-use glucagon). This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe improved forms of older drugs will be commercially successful.
Analysts' consensus forecast for the overall market share price
Xeris Biopharma (XERS) is a tech-focused pharma company. They don't search for new drugs, but rather improve existing ones (by converting powders into stable liquid forms). This chart, reflecting expert expectations, has little impact on their niche, but overall pessimism is dampening investor appetite for small biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Xeris Biopharma
Xeris is a pharmaceutical company solving the compounding problem. Their technologies (XeriSol, XeriJect) enable the creation of ready-to-use, stable liquid forms of injectable drugs. This graph is an indicator of their platform. It likely aggregates sales growth of their own products (Gvoke) and their success in partnering with other pharmaceutical companies.
AKIMA Market Segment Index - Specialized pharma
Xeris (XERS) is a biotech leader in stable liquid drug technologies; the company uses its platforms (XeriSol) to create ready-to-use injections (Gvoke – glucagon). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this technology (R&D platform) model (XERS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Xeris Biopharma is a biopharmaceutical company using its formulation technologies to create ready-to-use medications (diabetes, endocrinology). This chart, reflecting the market average, provides a macro backdrop. It helps assess how Xeris, as it commercializes its portfolio, compares to overall economic trends.
